Libertini M, et al. - Authors evaluated the data on the effectiveness of anti-oestrogen drug tamoxifen and optimum methods of response assessment for the treatment of aggressive fibromatosis. They identified a retrospective database to identify consecutive patients diagnosed with aggressive fibromatosis (AF) and treated with tamoxifen plus/minus non-steroidal anti-inflammatory drugs at the tertiary referral centre between 2007 and 2014. Findings suggested that on MRI, no relationship was identified between symptomatic benefit and response by RECIST 1.1. Endpoints ought to be incorporated by prospective studies in AF focusing on patient symptoms.